Satoshi Ishikura

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5497276/publications.pdf

Version: 2024-02-01

516215 433756 2,183 31 16 31 citations h-index g-index papers 31 31 31 1591 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Definitive Chemoradiotherapy for T4 and/or M1 Lymph Node Squamous Cell Carcinoma of the Esophagus. Journal of Clinical Oncology, 1999, 17, 2915-2915.	0.8	394
2	Long-Term Toxicity After Definitive Chemoradiotherapy for Squamous Cell Carcinoma of the Thoracic Esophagus. Journal of Clinical Oncology, 2003, 21, 2697-2702.	0.8	355
3	Phase II Study of Chemoradiotherapy With 5-Fluorouracil and Cisplatin for Stage Il–III Esophageal Squamous Cell Carcinoma: JCOG Trial (JCOG 9906). International Journal of Radiation Oncology Biology Physics, 2011, 81, 684-690.	0.4	303
4	A Phase II Trial of Chemoradiotherapy for Stage I Esophageal Squamous Cell Carcinoma: Japan Clinical Oncology Group Study (JCOG9708). Japanese Journal of Clinical Oncology, 2009, 39, 638-643.	0.6	275
5	Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T2–3Nany M0 squamous cell carcinoma of the esophagus. International Journal of Radiation Oncology Biology Physics, 2003, 57, 425-433.	0.4	198
6	Randomized study of lowâ€dose <i>versus</i> standardâ€dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). Cancer Science, 2015, 106, 407-412.	1.7	116
7	A Consensus-based Guideline Defining the Clinical Target Volume for Pelvic Lymph Nodes in External Beam Radiotherapy for Uterine Cervical Cancer. Japanese Journal of Clinical Oncology, 2010, 40, 456-463.	0.6	80
8	Quality Assurance of Radiotherapy in Cancer Treatment: Toward Improvement of Patient Safety and Quality of Care. Japanese Journal of Clinical Oncology, 2008, 38, 723-729.	0.6	59
9	A Consensus-based Guideline Defining Clinical Target Volume for Primary Disease in External Beam Radiotherapy for Intact Uterine Cervical Cancer. Japanese Journal of Clinical Oncology, 2011, 41, 1119-1126.	0.6	56
10	Interinstitutional Variations in Planning for Stereotactic Body Radiation Therapy for Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2007, 68, 416-425.	0.4	47
11	Multicenter prospective study of stereotactic body radiotherapy for previously untreated solitary primary hepatocellular carcinoma: The STRSPH study. Hepatology Research, 2021, 51, 461-471.	1.8	40
12	A Japan Clinical Oncology Group Trial for Stereotactic Body Radiation Therapy of Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2007, 2, S115-S117.	0.5	39
13	Dosimetric verification in participating institutions in a stereotactic body radiotherapy trial for stage I non-small cell lung cancer: Japan clinical oncology group trial (JCOG0403). Physics in Medicine and Biology, 2006, 51, 5409-5417.	1.6	34
14	An on-site audit system for dosimetry credentialing of intensity-modulated radiotherapy in Japanese Clinical Oncology Group (JCOG) clinical trials. Physica Medica, 2016, 32, 987-991.	0.4	23
15	Chemoradiotherapy in Elderly Patients With Non–Small-Cell Lung Cancer: Long-Term Follow-Up of a Randomized Trial (JCOG0301). Clinical Lung Cancer, 2018, 19, e619-e627.	1.1	23
16	Multi-institutional comparison of treatment planning using stereotactic ablative body radiotherapy for hepatocellular carcinoma – benchmark for a prospective multi-institutional study. Radiation Oncology, 2013, 8, 113.	1.2	17
17	Radiotherapy quality assurance review in a multi-center randomized trial of limited-disease small cell lung cancer: the Japan Clinical Oncology Group (JCOG) trial 0202. Radiation Oncology, 2009, 4, 16.	1.2	13
18	Optimal radiotherapy for non-small-cell lung cancer: current progress and future challenges. General Thoracic and Cardiovascular Surgery, 2012, 60, 127-131.	0.4	13

#	Article	IF	CITATIONS
19	Radiotherapy quality assurance review for a multi-center randomized trial of locally advanced esophageal cancer: the Japan Clinical Oncology Group (JCOG) trial 0303. International Journal of Clinical Oncology, 2012, 17, 105-111.	1.0	12
20	A virtual dosimetry audit – Towards transferability of gamma index analysis between clinical trial QA groups. Radiotherapy and Oncology, 2017, 125, 398-404.	0.3	12
21	Radiotherapy alone for stage IE ocular adnexal mucosa-associated lymphoid tissue lymphomas: long-term results. Radiation Oncology, 2020, 15, 25.	1.2	11
22	Lung Cancer in Japan. Journal of Thoracic Oncology, 2022, 17, 353-361.	0.5	10
23	JCOG Radiation Therapy Study Group: History and Achievements. Japanese Journal of Clinical Oncology, 2011, 41, 1241-1243.	0.6	9
24	Dummy-run for standardizing plan quality of intensity-modulated radiotherapy for postoperative uterine cervical cancer: Japan Clinical Oncology Group study (JCOG1402). Radiation Oncology, 2019, 14, 133.	1,2	8
25	An end-to-end postal audit test to examine the coincidence between the imaging isocenter and treatment beam isocenter of the IGRT linac system for Japan Clinical Oncology Group (JCOG) clinical trials. Physica Medica, 2018, 53, 145-152.	0.4	7
26	Accelerated Fractionation versus Conventional Fractionation Radiation Therapy for Glottic Cancer of T1-2NOMO Phase III Study: Japan Clinical Oncology Group Study (JCOG 0701). Japanese Journal of Clinical Oncology, 2008, 38, 387-389.	0.6	6
27	Liver phantom design and dosimetric verification in participating institutions for a proton beam therapy in patients with resectable hepatocellular carcinoma: Japan Clinical Oncology Group trial (JCOG1315C). Radiotherapy and Oncology, 2019, 140, 98-104.	0.3	5
28	An overview of the medical-physics-related verification system for radiotherapy multicenter clinical trials by the Medical Physics Working Group in the Japan Clinical Oncology Group–Radiation Therapy Study Group. Journal of Radiation Research, 2020, 61, 999-1008.	0.8	5
29	Study protocol for JCOG1807C (DEEP OCEAN): a interventional prospective trial to evaluate the efficacy and safety of durvalumab before and after operation or durvalumab as maintenance therapy after chemoradiotherapy against superior sulcus non-small cell lung cancer. Japanese Journal of Clinical Oncology, 2022, 52, 383-387.	0.6	5
30	Inter-institutional survival heterogeneity in chemoradiation therapy for esophageal cancer: exploratory analysis of the JCOG0303 study. Japanese Journal of Clinical Oncology, 2016, 46, 389-392.	0.6	4
31	Definitive chemoradiotherapy for squamous cell carcinoma of the esophagus: outcomes for borderline-resectable disease. Journal of Radiation Research, 2020, 61, 464-469.	0.8	4